Skip to main content

History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia.

Publication ,  Journal Article
Pae, C-U; Masand, PS; Marks, DM; Krulewicz, S; Peindl, K; Mannelli, P; Patkar, AA
Published in: Prog Neuropsychopharmacol Biol Psychiatry
August 31, 2009

BACKGROUND: Despite of a high comorbidity of depressive and/or anxiety disorders with fibromyalgia, information on the clinical implications of this comorbidity is limited but antidepressants are commonly prescribed to treat fibromyalgia in clinical practice. We investigated whether a history of depressive and/or anxiety disorders was associated with response to paroxetine controlled release (CR) in the treatment of fibromyalgia. METHODS: One hundred sixteen (116) fibromyalgia subjects were randomized to receive paroxetine CR or placebo for 12 weeks. The primary outcome was treatment response defined as >or=25% reduction in the Fibromyalgia Impact Questionnaire (FIQ) score. In multivariate logistic regression, we determined if a history of depression and/or anxiety disorders was an independent predictor of response to paroxetine CR. RESULTS: In logistic regression, the history of depression and/or anxiety did not predict treatment response as measured by >or=25% reduction in Fibromyalgia Impact Questionnaire (FIQ) score (OR=0.66, 95% CI=.29-1.49, Wald=0.97, p=0.32), while the drug status (paroxetine CR) was significantly associated with treatment response (OR=2.57, CI=1.2-5.61, Wald=5.5, p=0.02). CONCLUSION: A significant proportion of patients with fibromyalgia had a history of anxiety and or depressive disorders. However response to treatment of fibromyalgia symptoms with paroxetine CR was not associated with a history of depressive and/or anxiety disorders. Our findings need to be confirmed in more adequately-powered and well-designed subsequent studies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prog Neuropsychopharmacol Biol Psychiatry

DOI

EISSN

1878-4216

Publication Date

August 31, 2009

Volume

33

Issue

6

Start / End Page

996 / 1002

Location

England

Related Subject Headings

  • Treatment Outcome
  • Psychiatry
  • Predictive Value of Tests
  • Paroxetine
  • Pain Measurement
  • Middle Aged
  • Male
  • Humans
  • Fibromyalgia
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pae, C.-U., Masand, P. S., Marks, D. M., Krulewicz, S., Peindl, K., Mannelli, P., & Patkar, A. A. (2009). History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry, 33(6), 996–1002. https://doi.org/10.1016/j.pnpbp.2009.05.005
Pae, Chi-Un, Prakash S. Masand, David M. Marks, Stan Krulewicz, Kathleen Peindl, Paolo Mannelli, and Ashwin A. Patkar. “History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia.Prog Neuropsychopharmacol Biol Psychiatry 33, no. 6 (August 31, 2009): 996–1002. https://doi.org/10.1016/j.pnpbp.2009.05.005.

Published In

Prog Neuropsychopharmacol Biol Psychiatry

DOI

EISSN

1878-4216

Publication Date

August 31, 2009

Volume

33

Issue

6

Start / End Page

996 / 1002

Location

England

Related Subject Headings

  • Treatment Outcome
  • Psychiatry
  • Predictive Value of Tests
  • Paroxetine
  • Pain Measurement
  • Middle Aged
  • Male
  • Humans
  • Fibromyalgia
  • Female